A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Beijing InnoCare Pharma Tech Co., Ltd.
Updated on 28 February 2022
ct scan
platelet count
lymphoid leukemia
chronic lymphocytic leukemia
measurable disease
growth factor
lymphocytic leukemia
gilbert's syndrome
hepatitis b surface antigen
neutrophil count
blood transfusion
follicular lymphoma
mantle cell lymphoma
marginal zone lymphoma
renal function tests
btk inhibitor
hepatitis b core antibody
bone marrow infiltration


This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).

Condition Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
Treatment ICP-022, Orelabrutinib (ICP-022)
Clinical Study IdentifierNCT04014205
SponsorBeijing InnoCare Pharma Tech Co., Ltd.
Last Modified on28 February 2022


Yes No Not Sure

Inclusion Criteria

Signed Informed Consent
Age ≥ 18 years
Part 1: Patients with histologically confirmed relapsed or refractory B-cell malignancies, including Grades 1-3a FL, MZL, MCL, and CLL/SLL
Part 2: Patients with histologically confirmed B-cell malignancies including
r/r FL, r/r MZL and CLL/SLL with/without prior treatment
Life expectancy (in the opinion of the investigator) of ≥ 4 months
ECOG performance status of 0 ~1
Must have adequate organ function
Negative test results for HBV ([HBsAg (-)] and non-active HBV or HCV infection

Exclusion Criteria

Prior treatment with systemic immunotherapeutic agents
Known allergies to Orelabrutinib (ICP-022) or its excipients or infection with HIV
Treatment with any chemotherapeutic agent, or any other investigational therapies within 4 weeks prior to first dose of the study drug
History of allogeneic stem-cell (or other organ) transplantation or confirmed progressive PML
Concurrent use of warfarin or other vitamin K antagonists or anticoagulation therapies or strong CYP3A inhibitor
Recent infection requiring IV anti-infective treatment that was completed ≤ 14 days before the first dose of study drug
Pregnant or breast-feeding or intending to become pregnant during the study
Unresolved toxicities from prior anti-cancer therapy
Medically apparent CNS lymphoma or leptomeningeal disease
Current or previous history of CNS disease
Major surgery or significant traumatic injury < 28 days prior to the first dose of the study drug
Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug
Patients with another invasive malignancy in the last 2 years
Significant cardiovascular disease or active pulmonary disease
Received systemic immunosuppressive medications
Active uncontrolled infections
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note